Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $1.1 million.

  • Amylyx Pharmaceuticals' Change in Accured Expenses rose 108.35% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.8 million, marking a year-over-year decrease of 151.40%. This contributed to the annual value of -$59.8 million for FY2024, which is 376.94% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $1.1 million for Q3 2025, which was down 79.71% from $5.4 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $20.8 million during Q4 2023, with a 5-year trough of -$26.4 million in Q4 2024.
  • For the 3-year period, Amylyx Pharmaceuticals' Change in Accured Expenses averaged around -$4.0 million, with its median value being -$1.2 million (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 8,879.45% in 2024, then spiked by 143.08% in 2025.
  • Over the past 4 years, Amylyx Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $5.7 million in 2022, then tumbled by 102.58% to $20.8 million in 2023, then plummeted by 227.07% to -$26.4 million in 2024, then surged by 108.35% to $1.1 million in 2025.
  • Its Change in Accured Expenses stands at $1.1 million for Q3 2025, versus $5.4 million for Q2 2025 and -$11.9 million for Q1 2025.